Comparison of Peroperative Methotrexate Infusion With Postoperative Intra Silicon Oil Methotrexate Injections for Prevention of Proliferative Vitreoretinopathy Development After Vitrectomy for Rhegmatogenous Retinal Detachment Repair.

Status: Recruiting
Location: See location...
Intervention Type: Drug
Study Type: Interventional
Study Phase: Phase 1/Phase 2
SUMMARY

This clinical trial, involving participants with rhegmatogenous retinal detachment, aims to compare Methotrexate Usage Techniques in preventing Proliferative Vitreoretinopathy (PVR) after vitrectomy. The study will evaluate the development of PVR, retinal detachment recurrence, and improvement in visual acuity. Participants will undergo retinal detachment surgery using the vitrectomy technique and will be divided into two groups. One group will receive Methotrexate infusion during surgery, while the other will receive repeated Methotrexate injections post-surgery. The researcher will analyze and compare outcomes between the two groups.

Eligibility
Participation Requirements
Sex: All
Minimum Age: 20
Maximum Age: 70
Healthy Volunteers: f
View:

• Rhegmatogenous Retinal Detachment

Locations
Other Locations
Pakistan
Sahiwal Medical College & Teaching Hospital, Sahiwal, Pakistan
RECRUITING
Sahiwal
Contact Information
Primary
Ahmad Z Jamil, FCPS,FRCS
ahmadzeeshandr@gmail.com
+923334853851
Backup
Muhammad H Jamil, FRCS,FCPS
dr.m.hannan@gmail.com
+923336113166
Time Frame
Start Date: 2024-03
Estimated Completion Date: 2025-05
Participants
Target number of participants: 120
Treatments
Active_comparator: Group 1
Group 1 will be regarded as control group and per operative methotrexate infusion will be used by mixing 75 mg of methotrexate into one litre of BSS solution.
Experimental: Group 2
Group 2 will be regarded as the study group and will receive 500 µg of intra-silicon oil methotrexate at the end of the surgery and then at 1st, 2nd, 3rd , 4th and 6th post operative weeks.
Related Therapeutic Areas
Sponsors
Leads: University of Health Sciences Lahore

This content was sourced from clinicaltrials.gov